Global HER2-negative Breast Cancer Sales Market Report Forecast 2017 to 2022

November 2017 | 130 pages | ID: G421C7762B3EN
S&P Consulting

Abstracts

Delivery of the Report will take 2-3 working days once order is placed.

The report offers a comprehensive evaluation of the market. It does so via in-depth insights, understanding market evolution by tracking historical developments, and analyzing the present scenario and future projections based on optimistic and likely scenarios. Each research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology developments, types, applications, and the competitive landscape.

The study is a source of reliable data on:

• Key market segments and sub-segments
• Evolving market trends and dynamics
• Changing supply and demand scenarios
• Quantifying market opportunities through market sizing and market forecasting
• Tracking current trends/opportunities/challenges
• Competitive insights
• Opportunity mapping in terms of technological breakthroughs

This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. Geographies analyzed under this research report include:
United States
China
Europe
Japan

The Major players reported in the market include:
F. Hoffmann-La Roche
Novartis
Pfizer
AbbVie
AstraZeneca
BioMarin
Bristol-Myers Squibb
Eisai
Eli Lilly

Product Segment Analysis:
Type 1
Type 2
Type 3

Application Segment Analysis:
Application 1
Application 2
Application 3

Reasons for Buying this Report

• This report provides pin-point analysis for changing competitive dynamics
• It provides a forward looking perspective on different factors driving or restraining market growth
• It provides a six-year forecast assessed on the basis of how the market is predicted to grow
• It helps in understanding the key product segments and their future
• It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
• It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

It provides distinctive graphics and exemplified analysis of major market segments

Contents

1 HER2-NEGATIVE BREAST CANCER MARKET OVERVIEW

1.1 Product Overview and Scope of HER2-negative Breast Cancer
1.2 Classification of HER2-negative Breast Cancer
  1.2.1 Type
  1.2.2 Type
  1.2.3 Type
1.3 Application of HER2-negative Breast Cancer
  1.3.2 Application
  1.3.3 Application
  1.3.4 Application
1.4 HER2-negative Breast Cancer Market States Status and Prospect (2012-2022) by Regions
  1.4.1 United States
  1.4.2 China
  1.4.3 Europe
  1.4.4 Japan
1.5 Global Market Size of HER2-negative Breast Cancer (2012-2022)
  1.5.1 Global HER2-negative Breast Cancer Sales and Growth Rate (2012-2022)
  1.5.2 Global HER2-negative Breast Cancer Revenue and Growth Rate (2012-2022)

2 GLOBAL ECONOMIC IMPACT ON HER2-NEGATIVE BREAST CANCER INDUSTRY

2.1 Global Macroeconomic Environment Analysis
  2.1.1 Global Macroeconomic Analysis
  2.1.2 Global Macroeconomic Environment Development Trend
2.2 Global Macroeconomic Environment Analysis by Regions

3 HER2-NEGATIVE BREAST CANCER MANUFACTURING COST ANALYSIS

3.1 HER2-negative Breast Cancer Key Raw Materials Analysis
  3.1.1 Key Raw Materials
  3.1.2 Price Trend of Key Raw Materials
  3.1.3 Key Suppliers of Raw Materials
  3.1.4 Market Concentration Rate of Raw Materials
3.2 Proportion of Manufacturing Cost Structure
  3.2.1 Raw Materials
  3.2.2 Labor Cost
  3.2.3 Manufacturing Process Analysis of HER2-negative Breast Cancer

4 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

4.1 HER2-negative Breast Cancer Industrial Chain Analysis
4.2 Upstream Raw Materials Sourcing
4.3 Raw Materials Sources of HER2-negative Breast Cancer Major Manufacturers in 2016
4.4 Downstream Buyers

5 GLOBAL HER2-NEGATIVE BREAST CANCER COMPETITION BY MANUFACTURERS, TYPE AND APPLICATION

5.1 Global HER2-negative Breast Cancer Market Competition by Manufacturers
  5.1.1 Global HER2-negative Breast Cancer Sales and Market Share of Key Manufacturers (2012-2017)
  5.1.2 Global HER2-negative Breast Cancer Revenue and Share by Manufacturers (2012-2017)
5.2 Global HER2-negative Breast Cancer (Volume and Value) by Type
  5.5.1 Global HER2-negative Breast Cancer Sales and Market Share by Type (2012-2017)
  5.5.2 Global HER2-negative Breast Cancer Revenue and Market Share by Type (2012-2017)
5.3 Global HER2-negative Breast Cancer (Volume and Value) by Regions
  5.3.1 Global HER2-negative Breast Cancer Sales and Market Share by Regions (2012-2017)
  5.3.2 Global HER2-negative Breast Cancer Revenue and Market Share by Regions (2012-2017)
5.4 Global HER2-negative Breast Cancer (Volume) by Application

6 UNITED STATES HER2-NEGATIVE BREAST CANCER (VOLUME, VALUE AND SALES PRICE)

6.1 United States HER2-negative Breast Cancer Sales and Value (2012-2017)
  6.1.1 United States HER2-negative Breast Cancer Sales and Growth Rate (2012-2017)
  6.1.2 United States HER2-negative Breast Cancer Revenue and Growth Rate (2012-2017)
  6.1.3 United States HER2-negative Breast Cancer Sales Price Trend (2012-2017)
6.2 United States HER2-negative Breast Cancer Sales and Market Share by Manufacturers
6.3 United States HER2-negative Breast Cancer Sales and Market Share by Type
6.4 United States HER2-negative Breast Cancer Sales and Market Share by Application

7 CHINA HER2-NEGATIVE BREAST CANCER (VOLUME, VALUE AND SALES PRICE)

7.1 China HER2-negative Breast Cancer Sales and Value (2012-2017)
  7.1.1 China HER2-negative Breast Cancer Sales and Growth Rate (2012-2017)
  7.1.2 China HER2-negative Breast Cancer Revenue and Growth Rate (2012-2017)
  7.1.3 China HER2-negative Breast Cancer Sales Price Trend (2012-2017)
7.2 China HER2-negative Breast Cancer Sales and Market Share by Manufacturers
7.3 China HER2-negative Breast Cancer Sales and Market Share by Type
7.4 China HER2-negative Breast Cancer Sales and Market Share by Application

8 EUROPE HER2-NEGATIVE BREAST CANCER (VOLUME, VALUE AND SALES PRICE)

8.1 Europe HER2-negative Breast Cancer Sales and Value (2012-2017)
  8.1.1 Europe HER2-negative Breast Cancer Sales and Growth Rate (2012-2017)
  8.1.2 Europe HER2-negative Breast Cancer Revenue and Growth Rate (2012-2017)
  8.1.3 Europe HER2-negative Breast Cancer Sales Price Trend (2012-2017)
8.2 Europe HER2-negative Breast Cancer Sales and Market Share by Manufacturers
8.3 Europe HER2-negative Breast Cancer Sales and Market Share by Type
8.4 Europe HER2-negative Breast Cancer Sales and Market Share by Application

9 JAPAN HER2-NEGATIVE BREAST CANCER (VOLUME, VALUE AND SALES PRICE)

9.1 Japan HER2-negative Breast Cancer Sales and Value (2012-2017)
  9.1.1 Japan HER2-negative Breast Cancer Sales and Growth Rate (2012-2017)
  9.1.2 Japan HER2-negative Breast Cancer Revenue and Growth Rate (2012-2017)
  9.1.3 Japan HER2-negative Breast Cancer Sales Price Trend (2012-2017)
9.2 Japan HER2-negative Breast Cancer Sales and Market Share by Manufacturers
9.3 Japan HER2-negative Breast Cancer Sales and Market Share by Type
9.4 Japan HER2-negative Breast Cancer Sales and Market Share by Application

10 GLOBAL HER2-NEGATIVE BREAST CANCER MANUFACTURERS ANALYSIS

10.1 F. Hoffmann-La Roche
  10.1.1 Company Basic Information, Manufacturing Base and Competitors
  10.1.2 Product Type, Application and Specification
  10.1.3 Sales, Revenue, Price and Gross Margin (2012-2017)
  10.1.4 Business Overview
10.2 Novartis
  10.2.1 Company Basic Information, Manufacturing Base and Competitors
  10.2.2 Product Type, Application and Specification
  10.2.3 Sales, Revenue, Price and Gross Margin (2012-2017)
  10.2.4 Business Overview
10.3 Pfizer
  10.3.1 Company Basic Information, Manufacturing Base and Competitors
  10.3.2 Product Type, Application and Specification
  10.3.3 Sales, Revenue, Price and Gross Margin (2012-2017)
  10.3.4 Business Overview
10.4 AbbVie
  10.4.1 Company Basic Information, Manufacturing Base and Competitors
  10.4.2 Product Type, Application and Specification
  10.4.3 Sales, Revenue, Price and Gross Margin (2012-2017)
  10.4.4 Business Overview
10.5 AstraZeneca
  10.5.1 Company Basic Information, Manufacturing Base and Competitors
  10.5.2 Product Type, Application and Specification
  10.5.3 Sales, Revenue, Price and Gross Margin (2012-2017)
  10.5.4 Business Overview
10.6 BioMarin
  10.6.1 Company Basic Information, Manufacturing Base and Competitors
  10.6.2 Product Type, Application and Specification
  10.6.3 Sales, Revenue, Price and Gross Margin (2012-2017)
  10.6.4 Business Overview
10.7 Bristol-Myers Squibb
  10.7.1 Company Basic Information, Manufacturing Base and Competitors
  10.7.2 Product Type, Application and Specification
  10.7.3 Sales, Revenue, Price and Gross Margin (2012-2017)
  10.7.4 Business Overview
10.8 Eisai
  10.8.1 Company Basic Information, Manufacturing Base and Competitors
  10.8.2 Product Type, Application and Specification
  10.8.3 Sales, Revenue, Price and Gross Margin (2012-2017)
  10.8.4 Business Overview
10.9 Eli Lilly
  10.9.1 Company Basic Information, Manufacturing Base and Competitors
  10.9.2 Product Type, Application and Specification
  10.9.3 Sales, Revenue, Price and Gross Margin (2012-2017)
  10.9.4 Business Overview

11 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

11.1 Marketing Channel
  11.1.1 Direct Marketing
  11.1.2 Indirect Marketing
  11.1.3 Marketing Channel Development Trend
11.2 Market Positioning
  11.2.1 Pricing Strategy
  11.2.2 Brand Strategy
  11.2.3 Target Client
11.3 Distributors/Traders List

12 MARKET EFFECT FACTORS ANALYSIS

12.1 Technology Progress/Risk
  12.1.1 Substitutes Threat
  12.1.2 Technology Progress in Related Industry
12.2 Consumer Needs/Customer Preference Change
12.3 Economic/Political Environmental Change

13 GLOBAL HER2-NEGATIVE BREAST CANCER MARKET FORECAST (2017-2022)

13.1 Global HER2-negative Breast Cancer Sales, Revenue Forecast (2017-2022)
13.2 Global HER2-negative Breast Cancer Sales Forecast by Regions (2017-2022)
13.3 Global HER2-negative Breast Cancer Sales Forecast by Type (2017-2022)
13.4 Global HER2-negative Breast Cancer Sales Forecast by Application (2017-2022)

14 APPENDIX

List Of Tables

LIST OF TABLES AND FIGURES

Figure Picture of HER2-negative Breast Cancer
Table Classification of HER2-negative Breast Cancer
Figure Global Sales Market Share of HER2-negative Breast Cancer by Type in 2016
Table Applications of HER2-negative Breast Cancer
Figure Global Sales Market Share of HER2-negative Breast Cancer by Application in 2016
Figure United States HER2-negative Breast Cancer Revenue and Growth Rate (2012-2022)
Figure China HER2-negative Breast Cancer Revenue and Growth Rate (2012-2022)
Figure Europe HER2-negative Breast Cancer Revenue and Growth Rate (2012-2022)
Figure Japan HER2-negative Breast Cancer Revenue and Growth Rate (2012-2022)
Figure Global HER2-negative Breast Cancer Sales and Growth Rate (2012-2022)
Figure Global HER2-negative Breast Cancer Revenue and Growth Rate (2012-2022)
Table Global HER2-negative Breast Cancer Sales of Key Manufacturers (2012-2017)
Table Global HER2-negative Breast Cancer Sales Share by Manufacturers (2012-2017)
Figure 2015 HER2-negative Breast Cancer Sales Share by Manufacturers
Figure 2016 HER2-negative Breast Cancer Sales Share by Manufacturers
Table Global HER2-negative Breast Cancer Revenue by Manufacturers (2012-2017)
Table Global HER2-negative Breast Cancer Revenue Share by Manufacturers (2012-2017)
Table 2015 Global HER2-negative Breast Cancer Revenue Share by Manufacturers
Table 2016 Global HER2-negative Breast Cancer Revenue Share by Manufacturers
Table Global HER2-negative Breast Cancer Sales and Market Share by Type (2012-2017)
Table Global HER2-negative Breast Cancer Sales Share by Type (2012-2017)
Figure Sales Market Share of HER2-negative Breast Cancer by Type (2012-2017)
Figure Global HER2-negative Breast Cancer Sales Growth Rate by Type (2012-2017)
Table Global HER2-negative Breast Cancer Revenue and Market Share by Type (2012-2017)
Table Global HER2-negative Breast Cancer Revenue Share by Type (2012-2017)
Figure Revenue Market Share of HER2-negative Breast Cancer by Type (2012-2017)
Figure Global HER2-negative Breast Cancer Revenue Growth Rate by Type (2012-2017)
Table Global HER2-negative Breast Cancer Sales and Market Share by Regions (2012-2017)
Table Global HER2-negative Breast Cancer Sales Share by Regions (2012-2017)
Figure Sales Market Share of HER2-negative Breast Cancer by Regions (2012-2017)
Figure Global HER2-negative Breast Cancer Sales Growth Rate by Regions (2012-2017)
Table Global HER2-negative Breast Cancer Revenue and Market Share by Regions (2012-2017)
Table Global HER2-negative Breast Cancer Revenue Share by Regions (2012-2017)
Figure Revenue Market Share of HER2-negative Breast Cancer by Regions (2012-2017)
Figure Global HER2-negative Breast Cancer Revenue Growth Rate by Regions (2012-2017)
Table Global HER2-negative Breast Cancer Sales and Market Share by Application (2012-2017)
Table Global HER2-negative Breast Cancer Sales Share by Application (2012-2017)
Figure Sales Market Share of HER2-negative Breast Cancer by Application (2012-2017)
Figure Global HER2-negative Breast Cancer Sales Growth Rate by Application (2012-2017)
Figure United States HER2-negative Breast Cancer Sales and Growth Rate (2012-2017)
Figure United States HER2-negative Breast Cancer Revenue and Growth Rate (2012-2017)
Figure United States HER2-negative Breast Cancer Sales Price Trend (2012-2017)
Table United States HER2-negative Breast Cancer Sales by Manufacturers (2012-2017)
Table United States HER2-negative Breast Cancer Market Share by Manufacturers (2012-2017)
Table United States HER2-negative Breast Cancer Sales by Type (2012-2017)
Table United States HER2-negative Breast Cancer Market Share by Type (2012-2017)
Table United States HER2-negative Breast Cancer Sales by Application (2012-2017)
Table United States HER2-negative Breast Cancer Market Share by Application (2012-2017)
Figure China HER2-negative Breast Cancer Sales and Growth Rate (2012-2017)
Figure China HER2-negative Breast Cancer Revenue and Growth Rate (2012-2017)
Figure China HER2-negative Breast Cancer Sales Price Trend (2012-2017)
Table China HER2-negative Breast Cancer Sales by Manufacturers (2012-2017)
Table China HER2-negative Breast Cancer Market Share by Manufacturers (2012-2017)
Table China HER2-negative Breast Cancer Sales by Type (2012-2017)
Table China HER2-negative Breast Cancer Market Share by Type (2012-2017)
Table China HER2-negative Breast Cancer Sales by Application (2012-2017)
Table China HER2-negative Breast Cancer Market Share by Application (2012-2017)
Figure Europe HER2-negative Breast Cancer Sales and Growth Rate (2012-2017)
Figure Europe HER2-negative Breast Cancer Revenue and Growth Rate (2012-2017)
Figure Europe HER2-negative Breast Cancer Sales Price Trend (2012-2017)
Table Europe HER2-negative Breast Cancer Sales by Manufacturers (2012-2017)
Table Europe HER2-negative Breast Cancer Market Share by Manufacturers (2012-2017)
Table Europe HER2-negative Breast Cancer Sales by Type (2012-2017)
Table Europe HER2-negative Breast Cancer Market Share by Type (2012-2017)
Table Europe HER2-negative Breast Cancer Sales by Application (2012-2017)
Table Europe HER2-negative Breast Cancer Market Share by Application (2012-2017)
Figure Japan HER2-negative Breast Cancer Sales and Growth Rate (2012-2017)
Figure Japan HER2-negative Breast Cancer Revenue and Growth Rate (2012-2017)
Figure Japan HER2-negative Breast Cancer Sales Price Trend (2012-2017)
Table Japan HER2-negative Breast Cancer Sales by Manufacturers (2012-2017)
Table Japan HER2-negative Breast Cancer Market Share by Manufacturers (2012-2017)
Table Japan HER2-negative Breast Cancer Sales by Type (2012-2017)
Table Japan HER2-negative Breast Cancer Market Share by Type (2012-2017)
Table Japan HER2-negative Breast Cancer Sales by Application (2012-2017)
Table Japan HER2-negative Breast Cancer Market Share by Application (2012-2017)
Table F. Hoffmann-La Roche Basic Information List
Table F. Hoffmann-La Roche HER2-negative Breast Cancer Sales, Revenue, Price and Gross Margin (2012-2017)
Figure F. Hoffmann-La Roche HER2-negative Breast Cancer Global Market Share (2012-2017)
Table Novartis Basic Information List
Table Novartis HER2-negative Breast Cancer Sales, Revenue, Price and Gross Margin (2012-2017)
Figure Novartis HER2-negative Breast Cancer Global Market Share (2012-2017)
Table Pfizer Basic Information List
Table Pfizer HER2-negative Breast Cancer Sales, Revenue, Price and Gross Margin (2012-2017)
Figure Pfizer HER2-negative Breast Cancer Global Market Share (2012-2017)
Table AbbVie Basic Information List
Table AbbVie HER2-negative Breast Cancer Sales, Revenue, Price and Gross Margin (2012-2017)
Figure AbbVie HER2-negative Breast Cancer Global Market Share (2012-2017)
Table AstraZeneca Basic Information List
Table AstraZeneca HER2-negative Breast Cancer Sales, Revenue, Price and Gross Margin (2012-2017)
Figure AstraZeneca HER2-negative Breast Cancer Global Market Share (2012-2017)
Table BioMarin Basic Information List
Table BioMarin HER2-negative Breast Cancer Sales, Revenue, Price and Gross Margin (2012-2017)
Figure BioMarin HER2-negative Breast Cancer Global Market Share (2012-2017)
Table Bristol-Myers Squibb Basic Information List
Table Bristol-Myers Squibb HER2-negative Breast Cancer Sales, Revenue, Price and Gross Margin (2012-2017)
Figure Bristol-Myers Squibb HER2-negative Breast Cancer Global Market Share (2012-2017)
Table Eisai Basic Information List
Table Eisai HER2-negative Breast Cancer Sales, Revenue, Price and Gross Margin (2012-2017)
Figure Eisai HER2-negative Breast Cancer Global Market Share (2012-2017)
Table Eli Lilly Basic Information List
Table Eli Lilly HER2-negative Breast Cancer Sales, Revenue, Price and Gross Margin (2012-2017)
Figure Eli Lilly HER2-negative Breast Cancer Global Market Share (2012-2017)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of HER2-negative Breast Cancer
Figure Manufacturing Process Analysis of HER2-negative Breast Cancer
Figure HER2-negative Breast Cancer Industrial Chain Analysis
Table Raw Materials Sources of HER2-negative Breast Cancer Major Manufacturers in 2016
Table Major Buyers of HER2-negative Breast Cancer
Table Distributors/Traders List
Figure Global HER2-negative Breast Cancer Sales and Growth Rate Forecast (2017-2022)
Figure Global HER2-negative Breast Cancer Revenue and Growth Rate Forecast (2017-2022)
Table Global HER2-negative Breast Cancer Sales Forecast by Regions (2017-2022)
Table Global HER2-negative Breast Cancer Sales Forecast by Type (2017-2022)
Table Global HER2-negative Breast Cancer Sales Forecast by Application (2017-2022)

COMPANIES MENTIONED

F. Hoffmann-La Roche
Novartis
Pfizer
AbbVie
AstraZeneca
BioMarin
Bristol-Myers Squibb
Eisai
Eli Lilly
Galena Biopharma
Incyte
Merck
Merck Serono
Merrimack
Nektar
Tesaro